Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Amortization - Intangibles (2017 - 2022)

Historic Amortization - Intangibles for Avalo Therapeutics (AVTX) over the last 6 years, with Q1 2022 value amounting to $38000.0.

  • Avalo Therapeutics' Amortization - Intangibles fell 9103.77% to $38000.0 in Q1 2022 from the same period last year, while for Dec 2022 it was $38000.0, marking a year-over-year decrease of 9754.36%. This contributed to the annual value of $38000.0 for FY2022, which is 9754.52% down from last year.
  • Avalo Therapeutics' Amortization - Intangibles amounted to $38000.0 in Q1 2022, which was down 9103.77% from $267000.0 recorded in Q4 2021.
  • Avalo Therapeutics' 5-year Amortization - Intangibles high stood at $1.2 million for Q2 2018, and its period low was -$1.5 million during Q4 2018.
  • For the 5-year period, Avalo Therapeutics' Amortization - Intangibles averaged around $382032.1, with its median value being $404000.0 (2020).
  • In the last 5 years, Avalo Therapeutics' Amortization - Intangibles tumbled by 46857.93% in 2018 and then surged by 12250.76% in 2019.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Amortization - Intangibles stood at -$1.5 million in 2018, then skyrocketed by 122.51% to $334753.0 in 2019, then skyrocketed by 50.26% to $503000.0 in 2020, then crashed by 46.92% to $267000.0 in 2021, then tumbled by 85.77% to $38000.0 in 2022.
  • Its last three reported values are $38000.0 in Q1 2022, $267000.0 for Q4 2021, and $428000.0 during Q3 2021.